Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Endo International plc (ENDP) USD0.0001

Sell:$4.15 Buy:$4.16 Change: $0.67 (19.20%)
NASDAQ:0.30%
Market closed |  Prices as at close on 16 October 2019 | Switch to live prices |
Sell:$4.15
Buy:$4.16
Change: $0.67 (19.20%)
Market closed |  Prices as at close on 16 October 2019 | Switch to live prices |
Sell:$4.15
Buy:$4.16
Change: $0.67 (19.20%)
Market closed |  Prices as at close on 16 October 2019 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Endo International plc is a generics and specialty branded pharmaceutical company. The Company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals and International Pharmaceuticals. It has a portfolio of branded pharmaceuticals offered by its U.S. Branded Pharmaceuticals segment that includes brand names, such as Lidoderm, OPANA ER, Voltaren Gel, Percocet, Fortesta Gel, Testim, TESTOPEL, Aveed, Supprelin LA and XIAFLEX. Its non-branded U.S. Generic Pharmaceuticals portfolio consists of products, such as tablets, capsules, powders, injectables, liquids, nasal sprays, ophthalmics and patches. The Company's generics portfolio has a range of dosage forms and delivery systems. The International Pharmaceuticals segment includes various specialty pharmaceutical products for the Canadian, Latin American and world markets.

Contact details

Address:
Minerva House, Simmonscourt Road
DUBLIN
000 00
Ireland
Telephone:
+353 (1) 2682000
Website:
www.endo.com

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
ENDP
ISIN:
IE00BJ3V9050
Market cap:
$760.68 million
Shares in issue:
226.39 million
Sector:
Pharmaceuticals
Exchange:
NASDAQ
Country:
Ireland
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Roger Kimmel
    Independent Chairman of the Board
  • Paul Campanelli
    President, Chief Executive Officer, Director
  • Blaise Coleman
    Chief Financial Officer, Executive Vice President
  • Terrance Coughlin
    Chief Operating Officer, Executive Vice President
  • Patrick Barry
    Executive Vice President and Chief Commercial Officer
  • Domenico Ciarico
    Executive Vice President, Chief Commercial Officer - Sterile and Generics
  • Matthew Maletta
    Executive Vice President, Chief Legal Officer
  • Jack Boyle
    Senior Vice President, Financial Planning & Analysis, Interim Controller and Chief Accounting Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.